5.43
price down icon3.21%   -0.18
 
loading

Altimmune Inc Aktie (ALT) Neueste Nachrichten

pulisher
May 31, 2025

Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire

May 31, 2025
pulisher
May 29, 2025

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

May 28, 2025
pulisher
May 22, 2025

ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World

May 22, 2025
pulisher
May 21, 2025

Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN

May 21, 2025
pulisher
May 21, 2025

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN

May 21, 2025
pulisher
May 21, 2025

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com

May 21, 2025
pulisher
May 20, 2025

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga

May 20, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment - Investing.com

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World

May 19, 2025
pulisher
May 17, 2025

William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

(ALT) Proactive Strategies - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN

May 16, 2025
pulisher
May 16, 2025

Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter

May 16, 2025
pulisher
May 16, 2025

Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 16, 2025
pulisher
May 15, 2025

Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 15, 2025
pulisher
May 15, 2025

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN

May 15, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks

May 14, 2025
pulisher
May 14, 2025

Raymond James Financial Inc. Invests $88,000 in Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 14, 2025
pulisher
May 14, 2025

Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Report | ALT Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Altimmune Q1 2025 Earnings Call Transcript - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Altimmune secures $100 million credit facility for drug development - Investing.com

May 13, 2025
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):